mTORC2 contributes to the metabolic reprogramming in EGFR tyrosine-kinase inhibitor resistant cells in non-small cell lung cancer

Non-small cell lung cancer (NSCLC) patients with activating EGFR mutations are often successfully treated with EGFR tyrosine kinase inhibitor (TKI) such as erlotinib; however, treatment resistance inevitably occurs. Given tumor metabolism of glucose and therapeutic response are intimately linked, we...

Descripción completa

Detalles Bibliográficos
Autores principales: Chiang, Chun-Te, Demetriou, Alexandra N., Ung, Nolan, Choudhury, Niharika, Ghaffarian, Kimya, Ruderman, Daniel L., Mumenthaler, Shannon M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7443389/
https://www.ncbi.nlm.nih.gov/pubmed/30036610
http://dx.doi.org/10.1016/j.canlet.2018.07.025

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7443389/
https://www.ncbi.nlm.nih.gov/pubmed/30036610
http://dx.doi.org/10.1016/j.canlet.2018.07.025

Ejemplares similares